Stocks and InvestingStocks and Investing
Tue, August 16, 2011

ADEONA PHARMACEUTICALS INC (AMEX:AEN), Up By 6.10% ($0.05) From $0.820 After BUYINS.NET Report Predicted Stock Would Go Up Due


Published on 2011-08-16 05:27:16 - WOPRAI
  Print publication without navigation


August 16, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, August 12th 2011 stating that ADEONA PHARMACEUTICALS INC (AMEX:AEN) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/tools/symbol_stats.php?sym=aen

At the time this story was written, ADEONA PHARMACEUTICALS INC (AMEX:AEN) is Up By $0.05 (6.10%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

ADEONA PHARMACEUTICALS INC (AMEX:AEN) - Adeona Pharmaceuticals, Inc. operates as a pharmaceutical company that develops medicines for central nervous systems and autoimmune diseases. It primarily focuses to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them further to either commercialization or development collaboration. The company is developing various clinical-stage drug candidates that include Trimesta, an investigational oral drug for the treatment of relapsing remitting multiple sclerosis; Zinthionein, an oral, gastro-retentive, and sustained-release medical food candidate for the dietary management of Alzheimers disease and mild cognitive impairment; and Effirma, a centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome. It is also developing dnaJP1, an investigational oral drug for the treatment of rheumatoid arthritis; and CD4 Inhibitor 802-2, an investigational drug for the prevention of severe graft-versus-host disease. In addition, the company engages in commercializing serum-based diagnostic tests, including the CopperProof Panel to assist physicians in identifying patients with zinc deficiency and patients at risk of chronic copper toxicity due to impaired serum copper binding. Further, it involves in the manufacture, testing, and clinical development of tetrathiomolybate for Alzheimers, Parkinsons, and Huntingtons diseases. Adeona Pharmaceuticals, Inc. has a partnership with Meda AB, to develop flupirtine for the treatment of fibromyalgia syndrome. The company was founded in 2001 and is headquartered in Ann Arbor, Michigan.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net